Kazia Therapeutics stocks soar following Phase II/III win

Kazia Therapeutics’s stocks have skyrocketed by more than 250% after succeeding in a Phase II/III trial in glioblastoma.

The company announced positive results from an investigator-led platform trial, which was investigating its lead candidate, paxalisib, versus standard of care (SOC) for patients with glioblastoma.